Vinflunine ditartrate |
| Katalog-Nr.GC61584 |
Vinfluninditartrat ist der erste fluorierte Mikrotubuli-Inhibitor aus der Familie der Vinca-Alkaloide. Vinfluninditartrat hat antiangiogene, gefÄßzerstÖrende und antimetastatische AktivitÄten. Vinfluninditartrat kann zur Erforschung des Übergangszellkarzinoms des Urotheltrakts, des nicht-kleinzelligen Lungenkrebses und des Brustkrebses verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 194468-36-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Vinflunine ditartrate is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine ditartrate has anti-angiogenic, vascular-disrupting and anti-metastatic activities. Vinflunine ditartrate can be used for the research of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast[1][2].
Vinflunine (0.01-10 μM; 45 min) induces a rapid change in endothelial cell shape: cells retracted and assumed a rounded morphology[2].Vinflunine (0.01-10 μM; 1 h) disrupts newly formed capillary-like structures[2].Vinflunine (0.01-10 μM; 1 h) inhibits endothelial cell motility, with an IC50 of 0.71 μM[2].Vinflunine (0.001-10 μM; 1-72 h) inhibits endothelial cell proliferation in vitro[2].
Vinflunine (0.08-20 mg/kg; i.v.) reduces the number of experimental liver metastases by human LS174T colon cancer cells[2].Vinflunine (0.63-5 mg/kg; i.v. before and 2 d after Matrigel implantation) inhibits the bFGF-induced angiogenic response in mice in a dose-dependent manner[2]. Animal Model: Female athymic nude mice (BALB/c/Ola/Hsd-nu) were implanted LS174T cells[2]
[1]. Bennouna J, et, al. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008 Mar 15;14(6):1625-32. [2]. Kruczynski A, et, al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006 Nov;42(16):2821-32.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *